

# Serotonin, $\beta$ -Amyloid, and Cognition in Parkinson Disease

Vikas Kotagal, MD, MS,<sup>1,2</sup> Cathie Spino, ScD,<sup>3,4</sup>  
 Nicolaas I. Bohnen, MD, PhD,<sup>1,2,3,5</sup> Robert Koeppe, PhD,<sup>5</sup> and  
 Roger L. Albin, MD<sup>1,2,3</sup>

**Objective:** Serotonergic neurotransmission may modulate  $\beta$ -amyloid peptide ( $A\beta$ ) metabolism through upregulation of  $\alpha$ -secretase. Early Parkinson disease (PD) shows variable serotonergic denervation, which may impact  $A\beta$  deposition.

**Methods:** We conducted 3 analyses to explore associations between serotonergic neurotransmission and cerebral  $A\beta$  burden in PD. The first was a cross-sectional imaging study of PD subjects ( $n = 23$ ) using the serotonergic transporter positron emission tomography (PET) ligand [<sup>11</sup>C]3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB) and amyloid PET Pittsburgh compound B ([<sup>11</sup>C]PiB). The second was a baseline study of Parkinson's Progression Markers Initiative (PPMI) subjects exploring the influence of serotonergic medications on cerebrospinal fluid (CSF)  $A\beta$ -42 levels ( $n = 389$ ), controlling for age, sex, Geriatric Depression Scale, disease duration, and education. Third, we fit an interval censored proportional hazard model with longitudinal PPMI data ( $n = 367$ ) to test whether serotonergic medication use associates with reduced risk of PD cognitive decline, defined as time to reach a Montreal Cognitive Assessment score  $\leq 20$ , adjusting for baseline caudate dopamine transporter [<sup>123</sup>I]ioflupane single photon emission computed tomography and CSF  $A\beta$ -42 levels.

**Results:** Serotonergic DASB distribution volume ratio (DVR) inversely associated with PiB DVR in the cerebral cortex (Pearson  $r = -0.478$ ,  $p = 0.021$ ) but not the striatum ( $r = -0.264$ ,  $p = 0.224$ ). In the baseline PPMI analysis, serotonergic medication use for  $\geq 6$  months associated with a lower level of CSF  $A\beta$ -42 ( $t = -2.20$ ,  $p = 0.029$ ). In the longitudinal PPMI model, baseline serotonergic medication use associated with a reduced risk of cognitive decline ( $t = -2.03$ ,  $p = 0.043$ ) after controlling for covariates.

**Interpretation:** Cortical  $A\beta$  burden in PD associates inversely with serotonergic innervation. Serotonergic medications may alter  $A\beta$  metabolism and reduce the risk of PD cognitive decline.

ANN NEUROL 2018;83:994–1002

Progressive cerebral  $\beta$ -amyloid peptide ( $A\beta$ ) plaque burden is linked to clinically meaningful outcomes—including cognitive decline<sup>1,2</sup> and gait impairments<sup>3,4</sup>—in Parkinson disease (PD) and synucleinopathy-associated dementias.  $A\beta$  plaque deposition, assessed by amyloid positron emission tomography (PET), is associated with prevalent cognitive impairment in parkinsonian conditions.<sup>5</sup> Reduced cerebrospinal fluid (CSF)  $A\beta$ -42 oligomers and factors influencing their metabolism are also consistently reported as risk factors for subsequent cognitive decline in PD without dementia.<sup>6–8</sup> Developing

strategies to alter the natural history of  $A\beta$  burden in PD may represent an untapped disease-modifying approach and is an emerging research priority.

Variable loss of serotonergic nerve terminals in the forebrain, striatum, and brainstem is described in PD.<sup>9,10</sup> Significant loss of serotonergic terminals is an early feature in a substantial fraction of PD subjects.<sup>7,8</sup> Preclinical experiments in Alzheimer disease (AD) mouse models by Cirrito et al showed that chronic exposure to either serotonin itself or the selective serotonin reuptake inhibitor (SSRI) citalopram reduced extracellular cerebral

View this article online at [wileyonlinelibrary.com](http://wileyonlinelibrary.com). DOI: 10.1002/ana.25236

Received Dec 7, 2017, and in revised form Mar 15, 2018. Accepted for publication Apr 7, 2018.

Address correspondence to Dr Kotagal, Building 14, North Campus Research Complex, University of Michigan, 2800 Plymouth Road, Ann Arbor, MI 48109. E-mail: [vikaskot@med.umich.edu](mailto:vikaskot@med.umich.edu)

From the <sup>1</sup>Department of Neurology, University of Michigan; <sup>2</sup>Veterans Affairs Ann Arbor Health System; <sup>3</sup>University of Michigan Morris K. Udall Center of Excellence for Parkinson's Disease Research; <sup>4</sup>Department of Biostatistics, School of Public Health, University of Michigan; and <sup>5</sup>Department of Radiology, Division of Nuclear Medicine, University of Michigan, Ann Arbor, MI.

Additional supporting information may be found online in the Supporting Information section at the end of the article.

$A\beta$  peptide concentrations and plaque burden in short- and long- term in vivo studies.<sup>11,12</sup> Serotonin and SSRIs are suggested to stimulate a serotonin G-protein–coupled receptor–linked intracellular cascade that favors the cleavage of amyloid precursor protein (APP) by  $\alpha$ -secretase, leading to reductions in toxic  $A\beta$  peptide amyloid generation and reduced plaque formation.<sup>11</sup> Serotonin medications may also promote efflux of toxic  $A\beta$  peptide species from the brain into the blood.<sup>13</sup> Other preclinical research supports the concept that serotonergic neurotransmission can favorably modulate APP processing.<sup>14–17</sup> If the same protective association between serotonin receptor activation and reduced amyloid burden exists in humans, a disease state such as PD with reductions in serotonergic tone offers a potential model for testing this hypothesis. In a small cohort, we previously reported that regional density of cortical and striatal serotonergic terminals in PD, measured by in vivo PET, showed inverse correlations with  $A\beta$  plaque burden.<sup>18</sup>

We present 3 analyses exploring associations between serotonergic neurotransmission and  $A\beta$  burden in PD, using different experimental designs to address 3 related hypotheses. First, using an identical multimodal imaging approach to our earlier study in a new cohort, we sought to replicate our findings that decreased cortical serotonergic innervation is inversely associated with the severity of cortical  $A\beta$  plaque burden in PD. Second, using baseline data from the multicenter Parkinson's Progression Markers Initiative (PPMI), we explored associations between serotonin medication use and CSF  $A\beta$ -42 levels. Third, we conducted a longitudinal analysis of PPMI data to test whether baseline serotonergic medication use associates with a protective effect on cognitive decline in PD, independent of existing heterogeneity in caudate dopamine transporter binding or baseline cerebral amyloid burden.

## Patients and Methods

### Study 1: Cross-Sectional Prospective PET Imaging Study


In a previous PD cohort ( $n = 13$ ), we reported inverse associations between cortical and striatal serotonergic terminal and amyloid PET findings.<sup>18</sup> To determine whether these findings were due to cohort-specific effects, we conducted a separate cross-sectional multimodal PET imaging study of 23 PD subjects. Inclusion criteria included age  $\geq 45$  years, a diagnosis of PD as determined by the UK Parkinson's Disease Society Brain Bank Clinical Diagnostic Criteria,<sup>19</sup> no evidence of atypical parkinsonism or neuroleptic-associated PD, no contraindications to undergoing magnetic resonance imaging (MRI) such as indwelling metal hardware in the body, and no exposure to

serotonergic medications, anticholinergic medications, or cholinesterase inhibitors in the last 2 months. This study was reviewed by the institutional review boards of the University of Michigan Medical School (IRBMED), and all subjects signed informed consent prior to study enrollment.

Regional serotonin terminal density was assessed with the serotonin transporter PET ligand [<sup>11</sup>C]3-amino-4-(2-dimethylaminomethyl-phenylsulfanyl)-benzonitrile (DASB), and cerebral amyloid plaque deposition was measured with [<sup>11</sup>C]Pittsburgh compound B (PiB) PET as described previously.<sup>18</sup> For 22 of the 23 subjects, all MRI, DASB, and PiB PET scans took place within 1 week of each other. In 1 subject, the DASB and PiB scans were separated by 41 days. All PET studies were performed with bolus and infusion dynamic imaging protocols. Cortical and subcortical segmentation was performed with FreeSurfer version 5 in the fully automated mode. All image frames were spatially coregistered within participants with a rigid-body transformation. Motion-corrected PET frames were spatially coregistered to the T1-weighted MRI using standard coregistration procedures in NeuroStat (<https://neurostat.neuro.utah.edu/>). Time activity curves for each volume of interest were generated from the spatially aligned PET frames. DASB and PiB distribution volume ratios (DVRs) were estimated by the Logan plot graphical analysis method<sup>20</sup> with the time–activity curves as the input function and with the inferior posterior cerebellum as reference tissue for both PiB and DASB. Pearson correlation coefficients were used to assess the relationship of PiB and DASB DVRs in the total cortical and striatal regions of interest. Using subject age, disease duration, years of education, and cortical DASB DVR as covariates, we also conducted a multivariate linear regression model with cortical PiB DVR as the outcome variable and a covariate significance level for retention in the final model of 0.1 using a backward-selection process. Interaction terms were tested in the covariates retained in the final model and were included at a  $p$  value threshold of 0.1.

### Study 2a: Cross-Sectional PPMI Baseline Analysis

The PPMI is a multicenter longitudinal observational study of PD (<http://www.ppmi-info.org/>). Curated PPMI datasets containing  $A\beta$ -42 measurements, primary diagnoses, and dopamine transporter (DaT) [<sup>123</sup>I]ioflupane single photon emission computed tomography (SPECT) results were downloaded on August 22, 2017. Datasets containing demographics and clinical nonmotor testing were downloaded between October 10, 2016 and January 13, 2017. PPMI subjects underwent screening evaluations (month 0), followed by baseline evaluations (typically at month 1), visit 1 evaluations (month 4), and subsequent evaluations on a scheduled basis—initially at 3-month intervals and then at 6-month intervals after visit 4 (month 13)—through a possible visit 12 (month 61). All subjects signed informed consent upon enrollment into the PPMI. This project, using publicly available coded PPMI data, was granted not-regulated status by the the University of Michigan IRBMED. Analyses were conducted in Stata 15 (StataCorp, College Station, TX) and SAS 9.4 (SAS Institute, Cary, NC).



**FIGURE 1: Diagram of subject selection from Parkinson's Progression Markers Initiative.** CSF = cerebrospinal fluid; DaT = dopamine transporter; MoCA = Montreal Cognitive Assessment; PD = Parkinson disease.

Eligible subjects for our baseline analyses were those who were coded as having a primary study diagnosis of “idiopathic PD” at the time of screening visit, who had a screening visit DaT scan evaluation, who had CSF A $\beta$ -42 tested at the baseline visit, documentation of serotonin medication use at the time, and who did not accrue an alternative primary study diagnosis at a subsequent study visit. Figure 1 provides an overview of our PPMI study cohorts. We categorized serotonergic medications to include SSRIs,<sup>21</sup> serotonin–norepinephrine reuptake inhibitors (SNRIs),<sup>22</sup> tricyclic antidepressants (TCAs),<sup>17</sup> bupropion,<sup>23</sup> lithium,<sup>24</sup> and St John's wort,<sup>25</sup> given that each of these compounds has been shown to influence serotonergic neurotransmission. In this cross-sectional baseline study aimed at understanding the influence of serotonin medications on CSF A $\beta$ -42, we categorized subjects as those taking serotonin medications for  $\geq 6$  months ( $n = 45$ ) versus others ( $n = 344$ ). Serotonin medication use was treated as a categorical variable (yes/no) and was not adjusted for dosing or weight. Age was defined as the difference between year of birth and year of study enrollment, and disease duration was defined as the number of years between when symptoms were first noticed by the subject and year of study enrollment. CSF A $\beta$ -42 levels<sup>26</sup> were measured at the baseline visit.

Baseline CSF A $\beta$ -42 was treated as the outcome variable of interest in a multivariate linear regression using baseline cross-sectional PPMI data. Covariates included serotonin medication use, age, sex, disease duration, self-reported years of education, and baseline Geriatric Depression Scale (GDS) score on the 15-item GDS. We aimed to control for the degree of depressive symptoms using the GDS because late-life depression is known to associate both with dementia risk and with CSF A $\beta$ -42 burden.<sup>27,28</sup> We controlled for years of education to account for the possibility that subjects receiving prescription


serotonin medications might have unmeasured differences in socioeconomic status relative to those not on serotonin medications.

### Study 2b: Longitudinal PPMI Proportional Hazard Analysis

We conducted a survival analysis in the PPMI cohort to explore the effects of serotonergic medications on cognitive decline in PD. PD subjects who had  $\geq 2$  Montreal Cognitive Assessment (MoCA) scores recorded over the duration of the study, who underwent DaT SPECT at screening, and who had a screening MoCA score of  $>20$  at study entry were eligible for inclusion (see Fig 1).

We chose progression to MoCA scores of  $\leq 20$  as our endpoint, given that this transition value (21 $\rightarrow$ 20) has been previously validated against full neuropsychological testing in PD as an optimal diagnostic cutoff point (as opposed to a “screening” cutoff value) for meeting neuropsychological criteria of impairment in at least 2 cognitive domains suggestive of dementia.<sup>29</sup> We aimed to define our MoCA endpoint as manifestation of a clear stage-progression milestone, and tried to differentiate this endpoint from a transient drop in scoring that might improve at the next visit. Subsequently, we defined our endpoint as having been met if a subject had  $\geq 2$  consecutive visits with MoCA scores  $\leq 20$  or if their final recorded MoCA score was  $\leq 20$ . We qualified time to event as the month correlating with the planned visit according to the PPMI schedule of activities: screening visit (month 0), visit 4 (month 13), visit 6 (month 25), visit 8 (month 37), visit 10 (month 49), through visit 12 (month 61). To account for the possibility of missed study visits and the likelihood of that not all study visits took place at the identical time interval, we conducted a survival analysis using interval censoring with a Weibull proportional hazard distribution. Subjects whose MoCA scores progressed from  $>20$  at screening visit (month 0) to  $\leq 20$  by visit 4 (month 13) were identified as having progressed to the MoCA endpoint in an interval between 1 and 13 months and were categorized as interval censored rather than left censored. All other subjects who did not progress to a MoCA score of 20 or less were considered right censored at the time of their final recorded MoCA score. Of note, an inclusion criterion for enrollment in the PPMI was that subjects were “not expected to require PD medication within at least 6 months from baseline” (<http://www.ppmi-info.org/study-design/>).<sup>30</sup> Subsequently, none of our longitudinal PPMI subjects were on dopaminergic PD medications at study enrollment.

We first tested the unadjusted bivariate associations between several different potential explanatory variables including the use of serotonergic medications at the time of baseline evaluation (Supplementary Table) in separate Cox proportional hazard analyses. Next, we tested associations in a multivariate model after adjusting for several baseline confounders. The nigrostriatal dopaminergic system is known to play a role in PD cognitive impairment, specifically dopamine terminal loss in the caudate nucleus.<sup>31,32</sup> We estimated this using mean bilateral caudate nucleus DaT SPECT measurements from the



**FIGURE 2:** Cortical [<sup>11</sup>C]Pittsburgh compound B (PiB; amyloid) versus [<sup>11</sup>C]3-amino-4-(2-dimethylaminomethyl-phenyl-sulfaryl)-benzonitrile (DASB; serotonin) positron emission tomography distribution volume ratio (DVR; n = 23).

PPMI.<sup>33</sup> We sought to control for heterogeneity in baseline amyloid status by using baseline CSF A $\beta$ -42 levels as a covariate as well. Covariates were tested to explore the assumption of proportional hazards. To test whether a serotonin-medication

effect on MoCA decline might vary across drug classes of differing specificity for serotonin-receptor modulation, we conducted 2 separate sensitivity analyses where the serotonin medication use categorical variable was restricted to either only those subjects taking SSRIs or those subjects taking either SSRIs or TCAs.

## Results

Demographic characteristics for the Study 1 cohort are presented in Table 1. In the multimodal PET imaging study, cortical serotonergic terminal density correlated inversely with cortical amyloid burden (Pearson  $r = -0.478$ ,  $p = 0.021$ ; Fig 2). Striatal serotonergic terminal density did not significantly correlate with striatal amyloid deposition (Pearson  $r = -0.264$ ,  $p = 0.224$ ). In our multivariate linear regression model of cortical PiB DVR, disease duration and cortical DASB DVR were retained at a covariate threshold of  $p < 0.1$ . The final model ( $F = 5.11$ ,  $p = 0.0161$ ) showed an  $R^2$  of 0.338, with a significant association seen for cortical DASB DVR ( $t = 8.13$ ,  $p = 0.0099$ ) and a

**TABLE 1. Subject Characteristics**

Characteristic	Study 1: PD PET Imaging Cohort	Study 2a: PPMI Cross-Sectional Baseline Cohort	Study 2b: PPMI Longitudinal Cohort
n	23	389	367
Baseline age, yr	66.2 (6.7) [48–79]	61.8 (9.6) [34–85]	61.7 (9.7) [34–85]
Male sex	17 (74%)	253 (65%)	238 (65%)
Disease duration, yr	4.9 (4.1) [1–12]	1.9 (2.0) [0–21]	1.9 (2.0) [0–21]
Hoehn and Yahr score	HY1 = 6, HY2 = 15, HY3 = 2	HY1 = 191, HY2 = 198	HY1 = 180, HY2 = 187
Education, yr	16.9 (3.1) [12–25]	15.6 (3.0) [5–26]	15.5 (2.9) [5–26]
MoCA score at screening	25.6 (2.4) [20–29]	27.2 (2.3) [17–30]	27.2 (2.1) [21–30]
Final MoCA score at the time of event/censoring	NA	NA	26.4 (3.3) [15–31]
Mean absolute decline in MoCA score between screening and final score at the time of event/censoring	NA	NA	0.8 (3.0) [–6 to +13]
GDS score at baseline	7.2 (4.5) [1–15] <sup>a</sup>	5.1 (1.6) [0–10]	5.1 (1.6) [0–10]
Cerebrospinal fluid A $\beta$ -42 levels at baseline, pg/ml	—	371.5 (101.5) [129.2–796.5]	373.2 (102.2) [129.2–796.5]
Mean cortical amyloid PiB PET distribution volume ratio	1.06 (0.021) [1.04–1.11]	—	—

Values are given as mean (standard deviation) [min–max] or count (%).

<sup>a</sup>This score represents the 30-item GDS score, whereas the PPMI cohorts used the 15-item GDS.

GDS = Geriatric Depression Scale; MoCA = Montreal Cognitive Assessment; NA = not applicable; PD = Parkinson disease; PET = positron emission tomography; PiB = [<sup>11</sup>C]Pittsburgh compound B; PPMI = Parkinson's Progression Markers Initiative; HY = Hoehn and Yahr score.

**TABLE 2. Baseline Parkinson's Progression Markers Initiative Cross-Sectional Multivariate Linear Regression Analysis (n = 389)**

Covariates	Beta	Standard Error	t Score	p	95% Confidence Interval for Beta Values
Age in years	-0.810	0.533	-1.52	0.129	-1.859, 0.238
Male sex	-28.971	11.002	-2.63	0.009	-50.603, -7.338
Disease duration in years	1.241	2.533	0.49	0.625	-3.740, 6.221
Years of education	0.067	1.718	0.04	0.969	-3.311, 3.446
Geriatric Depression Scale-15 score	-4.262	3.142	-1.36	0.176	-10.440, 1.915
Positive serotonin medication status for $\geq 6$ months	-35.874	16.341	-2.20	0.029	-68.004, -3.745

Dependent variable: baseline cerebrospinal fluid A $\beta$ -42 (pg/ml); overall model  $F = 2.35$ ,  $p = 0.0305$ .

nonsignificant associative trend for duration of disease ( $t = 3.32$ ,  $p = 0.0836$ ). There were no significant interactions between cortical DASB DVR and disease duration.

In Study 2a, subjects on serotonin medications for at least 6 months at baseline ( $n = 45$ ) did not differ significantly in CSF A $\beta$ -42 levels from subjects not receiving serotonin medications in unadjusted analyses (mean  $\pm$  standard error [SE]:  $348.5 \pm 15.0$ pg/ml vs  $374.5 \pm 5.5$ pg/ml;  $t = 1.62$ ,  $p = 0.11$ ). After adjusting for confounders, the multivariate linear regression analyses ( $n = 389$ ; Table 2) showed that male sex and use of serotonin medications for at least 6 months both associated with lower levels of CSF A $\beta$ -42 at baseline. Age, disease duration, years of education, and GDS score did not show significant associations.

A total of 367 subjects met inclusion criteria for the survival analysis (Study 2b) predicting time to a decline in MoCA score of  $\leq 20$ . Of these 367 subjects, 70 (19.1%) were using serotonergic medications at the

time of their baseline visit. Twenty-eight of the total 367 subjects progressed to develop an MoCA score of 20 as assessed at a subsequent study visit. In a bivariate Cox proportional hazard analysis, taking a serotonergic medication at baseline did not show a significant association with decline to an MoCA of  $\leq 20$  (see Supplementary Table). Table 3 shows the results of a multivariate interval censored model controlling for the confounder effects of screening caudate nucleus DaT SPECT binding ratio and baseline CSF A $\beta$ -42 levels. In this model, serotonergic medication use at baseline showed a protective association with reduced likelihood of MoCA decline. Sensitivity analyses of this interval censored multivariate model using different definitions of serotonin medications revealed comparable but nonsignificant trends between both SSRI ( $n = 49$  of 367, hazard ratio = 0.185, SE = 0.189, 95% confidence interval [CI] = 0.025–1.372,  $Z = -1.65$ ,  $p = 0.099$ ) use and/or the combination of either SSRI or TCA ( $n = 54$  of 367, hazard ratio = 0.170, SE = 0.173, 95% CI = 0.023–1.257,

**TABLE 3. Study 2b Multivariate Proportional Hazard Model of Time to Reach Montreal Cognitive Assessment Score of  $\leq 20$** 

Covariates	Hazard Ratio	Standard Error	Z score	p	95% Confidence Interval for Hazard Ratio
Mean bilateral caudate DaT SPECT binding ratio at screening	0.456	0.183	-1.96	0.050	0.208, 1.000
Serotonergic medication status at baseline	0.223	0.165	-2.03	0.043	0.052, 0.952
Mean baseline A $\beta$ -42 in pg/ml	0.993	0.002	-3.25	0.001	0.989, 0.997

Overall model likelihood ratio: chi-square = 22.70,  $p < 0.0001$ , 3 degrees of freedom.  
DaT = dopamine transporter; SPECT = single photon emission computed tomography.

$Z = -1.74$ ,  $p = 0.083$ ) use and the risk for MoCA decline.

## Discussion

We present findings from converging lines of evidence supporting the hypothesized relationship between serotonergic neurotransmission and cerebral amyloid burden in PD. Study 1 confirms our previous imaging findings of a relationship between reduced serotonin terminals in the cortex and the increased severity of cerebral amyloid plaque burden in PD. Study 2a shows an association between serotonergic medication exposure for  $\geq 6$  months and lower CSF A $\beta$ -42 levels. Study 2b suggests that serotonergic medication exposure at baseline is associated with a reduced risk for progression to a MoCA score of  $\leq 20$ . Collectively, these findings support the concept that serotonergic medications favorably associate and/or alter cerebral A $\beta$  peptide activity in PD.

Postmortem studies of PD show reductions in serotonin terminal markers in numerous cortical and subcortical regions.<sup>34,35</sup> Consistent with in vivo PET imaging results, analysis of postmortem specimens by Buddhala et al showed that serotonergic terminal loss in PD exhibits considerable variation, with many PD subjects exhibiting regional serotonin terminal marker levels comparable to those found in control subjects and others showing marked loss of serotonin terminal markers.<sup>34</sup> PET studies suggest that regional serotonin terminal loss is an early event in PD.<sup>10,36</sup> This early and heterogeneous loss of serotonergic terminals may suggest a possible causal role for serotonergic modulation of A $\beta$  peptide generation in PD, the latter of which is a later stage disease feature that also shows substantial heterogeneity in cortical plaque burden.<sup>5</sup> In contrast to our initial findings, we did not find a significant correlation between striatal DASB and PiB DVRs in the current cohort. This may reflect stage-specific associations not seen in our cohort, given that striatal amyloid burden has been described more commonly in PD with advanced cognitive impairment as opposed to early PD.<sup>37,38</sup> Within the range of values seen in our Study 1 cohort, however, disease duration did not appear to influence the association between cortical DASB and PiB DVRs. Understanding temporal associations between early regional serotonin terminal loss and progressive amyloid plaque deposition leading to local neuronal dysfunction may be a fruitful goal for future PD natural history studies.

Our Study 2a analysis results indicating lower CSF A $\beta$ -42 levels in PD subjects taking serotonergic medications are consistent with recent preclinical and clinical data suggesting that increasing serotonergic

neurotransmission reduces A $\beta$  peptide generation. Cirrito et al demonstrated that chronic oral administration of citalopram relative to placebo in an AD mouse model diminished extracellular A $\beta$  peptide levels and led to a 62% reduction in relative cortical amyloid plaque burden after 4 months.<sup>11</sup> In a retrospective analysis of 177 healthy controls, the duration of serotonin medication exposure correlated with reduced cortical amyloid PET binding.<sup>11</sup> A separate prospective randomized trial of young healthy adults showed that those receiving an acute 60mg dose of citalopram rather than placebo experienced a 38% reduction over about 2 days in CSF A $\beta$  peptide concentrations, and the kinetics of this reduction was consistent with reduced A $\beta$  peptide generation.<sup>12</sup> Although higher A $\beta$ -42 CSF levels are typically associated with better cognitive outcomes in PD, interpretation of A $\beta$ -42 CSF level data is not straightforward.

CSF A $\beta$ -42 CSF levels likely reflect complex interactions between A $\beta$ -42 peptide generation, clearance, and possibly sequestration in amyloid plaques. Some evidence suggests that reduced A $\beta$ -42 levels would be consistent with reduced risk of dementia. In vitro data indicate that the protective APP A673T mutation is associated with reduced A $\beta$ -42 generation.<sup>39</sup> Recent evidence from APP A673T mutation carriers shows reduced serum levels of A $\beta$ -42, which is expected to correlate with CSF A $\beta$ -42 levels.<sup>40</sup> Similarly, increased A $\beta$ -42 generation is predicted to increase dementia risk. Statistical modeling of CSF A $\beta$ -42 data from autosomal dominant AD (ADAD) mutant allele carriers followed in the Dominantly Inherited Alzheimer Network study suggests early elevation of CSF A $\beta$ -42 levels followed by decline around the estimated onset of manifest disease.<sup>41</sup> In this model, declining CSF A $\beta$ -42 levels in ADAD subjects is secondary to neurodegeneration causing diminished A $\beta$ -42 peptide generation and/or A $\beta$ -42 peptide sequestration in amyloid plaques. The implication is that the association between lower CSF A $\beta$ -42 levels and dementia risk is a consequence of more advanced pathology.

Our finding (Study 2b) that baseline serotonergic medication exposure reduced risk of progression to MoCA  $< 20$  is also consistent with a beneficial modulatory effect of serotonergic agents on A $\beta$ -42 peptide generation. Similar results were reported recently in a retrospective analysis of conversion from mild cognitive impairment to dementia in the Alzheimer Disease Neuroimaging cohort.<sup>42</sup> Antidepressant medications were also suggested to reduce dementia incidence in analyses from Kessing et al in datasets drawn from large Danish registries of prescription drugs.<sup>43,44</sup> Our sensitivity analyses did not show significant associations of SSRIs and SSRIs/TCA with time to MoCA decline. Given the relatively

similar hazard ratios but increased hazard ratio SEs for the serotonin medication use variable in these subgroup analyses, these findings may be a manifestation of an expected reduction in statistical power with fewer subjects subsequently identified as having the exposure of interest.<sup>45</sup> Alternatively, they may reflect either the possibility that nonserotonin neuronal systems are preferentially involved in altering the risk of PD cognitive decline or the possibility that only a low degree of serotonin receptor modulation may be needed to yield a protective cognitive effect.

Serotonergic medications are used early and often in PD to treat symptoms of depression, anxiety, sleep disorders, or other nonmotor features. In the PPMI cohort, about 20% of subjects were on serotonergic medications at baseline. A community-based PD registry study in Sweden estimated the rate to be 22% in home-dwelling individuals and 50% in those residing in an institution.<sup>46</sup> To date, PD trials that have studied the efficacy of SSRIs, SNRIs, or TCAs typically employed relatively short study assessment periods (weeks to months) focused on symptomatic modification of self-reported affective symptoms and have not measured cerebral amyloid burden.<sup>47,48</sup> One post hoc analysis of a 4-month randomized PD antidepressant trial showed no clear benefit of paroxetine or nortriptyline on cognitive performance relative to placebo but was limited to a small sample size and short follow-up duration.<sup>49</sup> The possible beneficial effect of certain TCAs on amyloid-linked cognitive decline may also be confounded by their anticholinergic properties. A systematic review by Moraros et al investigated the association between antidepressant drugs and dementia risk and found a higher unadjusted dementia risk in subjects initiated on antidepressants before age 65 years.<sup>50</sup> These findings are likely to be influenced by the severity and variable causes of comorbid depression. They do, however, raise the possibility that there may exist a critical time window for serotonergic neurodegeneration-induced acceleration of cerebral amyloid burden. This may be relevant for the design of future interventional studies. Our Study 2b clinical findings would benefit from validation not only in other PD cohorts but also in prospective longitudinal studies of aging that could control for drug class and dosing.

Limitations of our study include the possibility of differential censoring. Only a small fraction of eligible subjects progressed to an MoCA score of  $\leq 20$ , raising the possibility that some subjects with declining cognition might have been lost to follow-up and would thereby not be captured in this dataset. It is possible that such censoring occurred and may influence these data.

Subjects enrolled in the PPMI may represent a skewed population, given that their parkinsonian symptoms were not severe enough to require the use of dopaminergic medications at the time of enrollment. This cohort factor may limit the generalizability of our findings. Because of power concerns, we were not able to control for a greater number of covariates, given the limited number of subjects who did progress to the MoCA endpoint. Some PPMI subjects showed variability in MoCA scoring from one visit to the next. We chose our endpoint specifically for the purpose of accurately identifying newly developed probable dementia rather than as a screening cutoff for subjects at risk for dementia. This effort to more precisely define a cognitive state transition point limited the number of PPMI subjects who met our primary endpoint. This tradeoff, however, comes with improved precision as it relates to our assessment of baseline risk factors associated with longitudinal cognitive decline. Our previously published cross-sectional DASB-PiB PD PET imaging cohort<sup>18</sup> had an even higher mean age (68.38 years) and lower mean MoCA (24.3) than the 23-subject imaging cohort in Study 1. In the present analyses, subjects enrolled in Study 1 were older, had longer disease duration, and had lower MoCA scores than subjects in the PPMI. This may limit how translatable findings from Study 1 are to the cohort in Study 2 and vice versa. Conversely, these findings may also collectively shed light into different aspects of the natural history of serotonergic neurodegeneration across different disease stages in PD.

We acknowledge that our findings do not directly test the protective causal mechanism that we hypothesize exists between serotonergic medications,  $\alpha$ -secretase activity, and the degree of cerebral amyloid burden in PD. It is possible that subjects in this cohort receiving serotonergic medications from their personal clinicians may have other unmeasured factors that influence amyloid burden and/or cognition, including severity and subtypes of affective symptoms or factors that associate with greater access to care and prescription medications. Given the wide variety, dosing, and duration of use of serotonergic medications by subjects, we were not able to explore a dose–response relationship.

Developing treatments for different causes of cerebral amyloid burden is a goal relevant not only to PD but to a majority of patients affected by neurodegenerative diseases. Our PD findings are strengthened by the multicenter nature of the PPMI but would benefit from replication in other representative PD datasets. Serotonergic medications are well tolerated in PD patients, and SSRIs targeted against cerebral amyloid burden merit consideration for future PD clinical trials. Such trials

might be usefully enhanced by use of serotonin terminal imaging to select or stratify the subject population.

## Acknowledgment

We thank all study participants who generously donated their time and effort.

## Author Contributions

V.K., R.L.A., and N.I.B. designed the study. V.K., C.S., R.L.A., and R.A.K. acquired and analyzed the data. V.K., N.I.B., and R.L.A. drafted the manuscript, which was reviewed and revised by all coauthors.

## Potential Conflicts of Interest

Nothing to report.

## References

- Aarsland D, Creese B, Politis M, et al. Cognitive decline in Parkinson disease. *Nat Rev Neurol* 2017;13:217–231.
- Petrou M, Bohnen NI, Muller ML, et al. A $\beta$ -amyloid deposition in patients with Parkinson disease at risk for development of dementia. *Neurology* 2012;79:1161–1167.
- Rochester L, Galna B, Lord S, et al. Decrease in A $\beta$ 42 predicts dopa-resistant gait progression in early Parkinson disease. *Neurology* 2017;88:1501–1511.
- Muller ML, Frey KA, Petrou M, et al.  $\beta$ -Amyloid and postural instability and gait difficulty in Parkinson's disease at risk for dementia. *Mov Disord* 2013;28:296–301.
- Petrou M, Dwamena BA, Foerster BR, et al. Amyloid deposition in Parkinson's disease and cognitive impairment: a systematic review. *Mov Disord* 2015;30:928–935.
- Terrelonge M Jr, Marder KS, Weintraub D, Alcalay RN. CSF  $\beta$ -amyloid 1-42 predicts progression to cognitive impairment in newly diagnosed parkinson disease. *J Mol Neurosci* 2016;58:88–92.
- Brockmann K, Lerche S, Dilger SS, et al. SNPs in A $\beta$  clearance proteins: lower CSF A $\beta$ <sub>1-42</sub> levels and earlier onset of dementia in PD. *Neurology* 2017;89:2335–2340.
- Johar I, Mollenhauer B, Aarsland D. Cerebrospinal fluid biomarkers of cognitive decline in Parkinson's disease. *Int Rev Neurobiol* 2017;132:275–294.
- Albin RL, Koeppe RA, Bohnen NI, et al. Spared caudal brainstem SERT binding in early Parkinson's disease. *J Cereb Blood Flow Metab* 2008;28:441–444.
- Pagano G, Niccolini F, Fusar-Poli P, Politis M. Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies. *Ann Neurol* 2017;81:171–180.
- Cirrito JR, Disabato BM, Restivo JL, et al. Serotonin signaling is associated with lower amyloid- $\beta$  levels and plaques in transgenic mice and humans. *Proc Natl Acad Sci U S A* 2011;108:14968–14973.
- Sheline YI, West T, Yarasheski K, et al. An antidepressant decreases CSF A $\beta$  production in healthy individuals and in transgenic AD mice. *Sci Transl Med* 2014;6:236re4.
- Brenn A, Grube M, Jedlitschky G, et al. St. John's wort reduces beta-amyloid accumulation in a double transgenic Alzheimer's disease mouse model-role of P-glycoprotein. *Brain Pathol* 2014;24:18–24.
- Nitsch RM, Deng M, Growdon JH, Wurtman RJ. Serotonin 5-HT<sub>2a</sub> and 5-HT<sub>2c</sub> receptors stimulate amyloid precursor protein ectodomain secretion. *J Biol Chem* 1996;271:4188–4194.
- Postina R. Activation of  $\alpha$ -secretase cleavage. *J Neurochem* 2012;120(suppl 1):46–54.
- Lezoualc'h F. 5-HT<sub>4</sub> receptor and Alzheimer's disease: the amyloid connection. *Exp Neurol* 2007;205:325–329.
- Li X, Wang Q, Hu T, et al. A tricyclic antidepressant, amoxapine, reduces amyloid- $\beta$  generation through multiple serotonin receptor 6-mediated targets. *Sci Rep* 2017;7:4983.
- Kotagal V, Bohnen NI, Muller ML, et al. Cerebral amyloid deposition and serotonergic innervation in Parkinson disease. *Arch Neurol* 2012;69:1628–1631.
- Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. *J Neurol Neurosurg Psychiatry* 1992;55:181–184.
- Logan J, Fowler JS, Volkow ND, et al. Distribution volume ratios without blood sampling from graphical analysis of PET data. *J Cereb Blood Flow Metab* 1996;16:834–840.
- Dempsey CM, Mackenzie SM, Gargus A, et al. Serotonin (5HT), fluoxetine, imipramine and dopamine target distinct 5HT receptor signaling to modulate Caenorhabditis elegans egg-laying behavior. *Genetics* 2005;169:1425–1436.
- Wong DT. Duloxetine (LY 248686): an inhibitor of serotonin and noradrenaline uptake and an antidepressant drug candidate. *Expert Opin Investig Drugs* 1998;7:1691–1699.
- Pandhare A, Pappu AS, Wilms H, et al. The antidepressant bupropion is a negative allosteric modulator of serotonin type 3A receptors. *Neuropharmacology* 2017;113(pt A):89–99.
- Januel D, Massot O, Poirier MF, et al. Interaction of lithium with 5-HT(1B) receptors in depressed unipolar patients treated with clomipramine and lithium versus clomipramine and placebo: preliminary results. *Psychiatry Res* 2002;111:117–124.
- Butterweck V, Nahrstedt A, Evans J, et al. In vitro receptor screening of pure constituents of St. John's wort reveals novel interactions with a number of GPCRs. *Psychopharmacology* 2002;162:193–202.
- Kang JH, Irwin DJ, Chen-Plotkin AS, et al. Association of cerebrospinal fluid  $\beta$ -amyloid 1-42, T-tau, P-tau181, and  $\alpha$ -synuclein levels with clinical features of drug-naive patients with early Parkinson disease. *JAMA Neurol* 2013;70:1277–1287.
- Defrancesco M, Marksteiner J, Kemmler G, et al. Severity of depression impacts imminent conversion from mild cognitive impairment to Alzheimer's disease. *J Alzheimers Dis* 2017;59:1439–1448.
- Nascimento KK, Silva KP, Malloy-Diniz LF, et al. Plasma and cerebrospinal fluid amyloid- $\beta$  levels in late-life depression: a systematic review and meta-analysis. *J Psychiatr Res* 2015;69:35–41.
- Hoops S, Nazem S, Siderowf AD, et al. Validity of the MoCA and MMSE in the detection of MCI and dementia in Parkinson disease. *Neurology* 2009;73:1738–1745.
- The Parkinson Progression Marker Initiative (PPMI). *Prog Neurobiol* 2011;95:629–635.
- Pellecchia MT, Picillo M, Santangelo G, et al. Cognitive performances and DAT imaging in early Parkinson's disease with mild cognitive impairment: a preliminary study. *Acta Neurol Scand* 2015;131:275–281.
- Marquie M, Locascio JJ, Rentz DM, et al. Striatal and extrastriatal dopamine transporter levels relate to cognition in Lewy body diseases: an (11)C altropane positron emission tomography study. *Alzheimers Res Ther* 2014;6:52.
- Schrag A, Siddiqui UF, Anastasiou Z, et al. Clinical variables and biomarkers in prediction of cognitive impairment in patients with



- newly diagnosed Parkinson's disease: a cohort study. *Lancet Neurol* 2017;16:66–75.
34. Buddhala C, Loftin SK, Kuley BM, et al. Dopaminergic, serotonergic, and noradrenergic deficits in Parkinson disease. *Ann Clin Transl Neurol* 2015;2:949–959.
  35. Ogawa T, Matson WR, Beal MF, et al. Kynurenine pathway abnormalities in Parkinson's disease. *Neurology* 1992;42:1702–1706.
  36. Politis M, Wu K, Loane C, et al. Staging of serotonergic dysfunction in Parkinson's disease: an in vivo 11C-DASB PET study. *Neurobiol Dis* 2010;40:216–221.
  37. Kalaitzakis ME, Walls AJ, Pearce RK, Gentleman SM. Striatal A $\beta$  peptide deposition mirrors dementia and differentiates DLB and PDD from other parkinsonian syndromes. *Neurobiol Dis* 2011;41:377–384.
  38. Shah N, Frey KA, Muller ML, et al. Striatal and cortical  $\beta$ -amyloidopathy and cognition in Parkinson's disease. *Mov Disord* 2016;31:111–117.
  39. Maloney JA, Bainbridge T, Gustafson A, et al. Molecular mechanisms of Alzheimer disease protection by the A673T allele of amyloid precursor protein. *J Biol Chem* 2014;289:30990–31000.
  40. Martiskainen H, Herukka SK, Stancakova A, et al. Decreased plasma  $\beta$ -amyloid in the Alzheimer's disease APP A673T variant carriers. *Ann Neurol* 2017;82:128–132.
  41. Fagan AM, Xiong C, Jasielec MS, et al. Longitudinal change in CSF biomarkers in autosomal-dominant Alzheimer's disease. *Sci Transl Med* 2014;6:226ra30.
  42. Bartels C, Wagner M, Wolfsgruber S, et al. Impact of SSRI therapy on risk of conversion from mild cognitive impairment to Alzheimer's dementia in individuals with previous depression. *Am J Psychiatry* 2018;175:232–241.
  43. Kessing LV, Forman JL, Andersen PK. Do continued antidepressants protect against dementia in patients with severe depressive disorder? *Int Clin Psychopharmacol* 2011;26:316–322.
  44. Kessing LV, Sondergard L, Forman JL, Andersen PK. Antidepressants and dementia. *J Affect Disord* 2009;117:24–29.
  45. Hajian-Tilaki K. Sample size estimation in epidemiologic studies. *Caspian J Intern Med* 2011;2:289–298.
  46. Haasum Y, Fastbom J, Johnell K. Use of antidepressants in Parkinson's disease: a Swedish register-based study of over 1.5 million older people. *Parkinsonism Relat Disord* 2016;27:85–88.
  47. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. *Neurology* 2009;72:886–892.
  48. Richard IH, McDermott MP, Kurlan R, et al. A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. *Neurology* 2012;78:1229–1236.
  49. Dobkin RD, Menza M, Bienfait KL, et al. The impact of antidepressant treatment on cognitive functioning in depressed patients with Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 2010;22:188–195.
  50. Moraros J, Nwankwo C, Patten SB, Mousseau DD. The association of antidepressant drug usage with cognitive impairment or dementia, including Alzheimer disease: a systematic review and meta-analysis. *Depress Anxiety* 2017;34:217–226.